Medical Radiation Therapy Systems sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Medical Radiation Therapy Systems
1.1 - About Medical Radiation Therapy Systems sector
Companies in Medical Radiation Therapy Systems design and manufacture devices and software used to deliver therapeutic radiation to cancer patients. Offerings span external beam and internal radiation modalities, combining precise dose delivery with imaging, planning, and workflow tools. Strategic buyers in this category focus on clinical efficacy, safety, and operational reliability, enabling providers to treat more cases, personalize therapy, and maintain compliance across complex oncology service lines.
Typical capabilities include linear accelerators with image‑guided and intensity‑modulated delivery, proton therapy gantries, stereotactic radiosurgery and SBRT options, and brachytherapy systems. Vendors pair these with treatment planning algorithms, adaptive therapy software, cone‑beam CT and MRI integration, immobilization solutions, and end‑to‑end dosimetry and QA platforms. Many provide oncology information systems, interoperability with EMR/RIS/PACS, remote system monitoring, and professional services for commissioning, calibration, and regulatory documentation.
Primary customers include hospital radiation oncology departments, comprehensive cancer centers, and outpatient radiotherapy clinics. Outcomes delivered include higher precision and tumor control, reduced treatment times and toxicity through image guidance and adaptive planning, improved throughput via streamlined workflows, and stronger compliance with dosing and safety standards. Solutions also support data integration for multidisciplinary care and better asset utilization across multi‑site health systems.
2. Buyers in the Medical Radiation Therapy Systems sector
2.1 Top strategic acquirers of Medical Radiation Therapy Systems companies
RefleXion
- Description: Provider of biology-guided radiotherapy technology that fuses PET imaging with stereotactic radiotherapy, using tumors’ own emissions to steer precise, real-time radiation for localized and metastatic cancer while reducing exposure to healthy tissue.
- Key Products:
- Biology-Guided Radiotherapy (BgRT) Machine: Radiotherapy system that uses tumors’ PET emissions for real-time guidance, delivering accurate doses to moving targets while minimizing radiation to healthy tissue
- PET-Radiotherapy Localization Platform: Integrates PET imaging with stereotactic radiotherapy to localize, track and treat multiple tumors simultaneously in one session, reducing margins and motion-related inaccuracies.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Medical Radiation Therapy Systems sector
M&A buyer group 1: Oncology Informatics
Tempus
- Type: N/A
- Employees: ●●●●●
- Description: Provider of data-driven precision medicine solutions, including genomic profiling, pharmacogenomic testing, AI-powered imaging analytics and interoperable clinical integrations that deliver actionable insights for clinicians to improve diagnosis, treatment selection and research collaboration across oncology, cardiovascular disease and other conditions.
- Key Products:
- Analytical Machine Learning Platform: AI-driven system that analyzes expansive clinical and molecular data in real time, enabling physicians to choose personalized therapies based on actionable insights during patient care
- Tempus Next: Care pathway intelligence platform that identifies biomarker testing gaps, supports guideline-directed decisions, and helps oncologists deliver appropriate breast cancer treatments using integrated data analytics
- Tempus One Clinical Assistant: On-demand digital tool that streamlines complex clinical and genomic data, giving providers rapid, clear patient insights while reducing workflow burden through AI-enabled automation
- Fixed PDO Panels: Preclinical oncology R&D panels allowing researchers to test drug candidates—including small molecules, mAbs
- ADCs, cell and bispecific therapies—on patient-derived organoids to assess efficacy across modalities
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Medical Radiation Therapy Systems sector
3.1 - Buyout funds in the Medical Radiation Therapy Systems sector
2.2 - Strategic buyer groups for Medical Radiation Therapy Systems sector
4 - Top valuation comps for Medical Radiation Therapy Systems companies
4.2 - Public trading comparable groups for Medical Radiation Therapy Systems sector
Valuation benchmark group 1: Diagnostic Imaging and Clinical Diagnostics Companies
RadNet
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of diagnostic imaging services and information technology solutions, operating a network of outpatient imaging centers offering services including MRI, CT, PET/CT, X-ray, ultrasound, and mammography to enhance patient care and medical imaging infrastructure.
- Key Products:
- MRI: High-resolution magnetic resonance imaging services for detailed internal body scans
- CT: Computed tomography scans for cross-sectional imaging
- PET/CT: Positron emission tomography combined with CT for comprehensive imaging
- X-ray: Basic and advanced X-ray imaging services for diagnostic purposes
- Mammography: Advanced breast imaging services including digital and 3D mammography.